AS1948006

AS1948006 is a potent and selective small-molecule inhibitor of the transcription factor Forkhead box protein O1 (FOXO1), with an IC50 of approximately 50 nM in cell-free assays. Developed by Astellas Pharma, the compound functions by suppressing FOXO1-mediated transcriptional activity, which plays a critical role in regulating hepatic gluconeogenesis. In preclinical models of type 2 diabetes, AS1948006 has demonstrated the ability to lower blood glucose levels by inhibiting the expression of key gluconeogenic enzymes, such as glucose-6-phosphatase (G6Pase) and phosphoenolpyruvate carboxykinase (PEPCK). While primarily utilized as a chemical probe in metabolic research to investigate the role of FOXO1 in insulin resistance and hyperglycemia, it represents a pharmacological approach to treating metabolic disorders by targeting the FOXO1 signaling pathway.

Other names

FOXO1 inhibitor AS1948006FOXO-1 inhibitor AS1948006FOXO 1 inhibitor AS19480065-amino-7-(cyclohexylamino)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carboxylic acid